News
March 17, 2026: Safe Chain Solutions executives jailed for selling secondhand HIV meds
A federal judge sentenced brothers Charles and Patrick Boyd to a combined 38 years in prison for running a nationwide scheme that sold counterfeit and diverted HIV medications to U.S. pharmacies.
[...]March Drug Importation Madness
For a pretty dead policy idea, bulk drug importation has had a lot of news lately. Get the update!
[...]Safe Chain owners Charles and Patrick Boyd sentenced for nationwide black market HIV drug scheme
federal judge in Florida sentenced Charles and Patrick Boyd to a cumulative 38 years in prison. The brothers owned Safe Chain Solutions, a Cambridge, Maryland-based drug distributor at the center of a diversion ring that endangered the health of American patients by selling U.S. pharmacies over 85,00 counterfeit bottles of secondhand HIV medicine worth more than $250 million.
[...]March 10, 2026: Fake cancer drug distributor sentenced to almost four years in federal prison
Sanjay Kumar got 43 months for selling counterfeit Keytruda. PSM wrote federal agencies about a Super Bowl ad promoting diagnostic tests and compounded medicines with false claims.
[...]PSM applauds Indiana legislature for compounding and med spa reform
On February 26, 2026, PSM was glad to see the Indiana legislature pass SB 282, a bill that strengthens compounding and medical spa regulation to keep Indiana patients safer.
[...]March 2, 2026: Europol’s 2025 Operation Shield yielded $38m in counterfeit and illegal medicines; domestic and international news sheds light on GLP-1 crimes
As Europol seized a huge amounts of counterfeit pharmaceuticals abroad, a Kentucky legislator proposed a bill to regulate med spas after a constituent was seriously injured and adverse events related to weight loss drugs see surges across the US.
[...]February 23, 2026: State investigates whistleblower allegations of unsafe GLP-1 drug handling at Mochi Health-affiliated pharmacy.
Washington State investigators found serious violations at a Mochi Health-affiliated compounding pharmacy producing GLP-1s, and a med spa bill in Indiana hears public testimony about a med spa bill.
[...]Are dead insects in manufacturing areas enough to disqualify a firm from the FDA’s Green List for makers of GLP-1 API?
Industry experts told us that these two companies are on the FDA’s Green List, despite problematic inspections in late 2024 and early 2025. Learn what the inspectors found.
[...]Update on drug importation, February 2026
Well-meaning advocates continue to propose importing medicine from foreign countries to lower drug prices for Americans. Past efforts didn’t pay off financially and raised public health risks. Here’s the state of this issue today.
[...]February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter
A Pennsylvania compounding pharmacy received another FDA warning letter following a series of enforcement actions, including a $1 million state fine in October.
[...]